<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03509922</url>
  </required_header>
  <id_info>
    <org_study_id>YMC036</org_study_id>
    <nct_id>NCT03509922</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effectiveness of Sarpogrelate on Blood Viscosity in Adult Patients With High Blood Viscosity</brief_title>
  <official_title>A Randomized, Dose-controlled, Open-label, Parallel, 2-treatment Group, Single Center, Pilot Study to Evaluate the Effectiveness of Sarpogrelate on Blood Viscosity in Adult Patients With High Blood Viscosity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the effect of sarpogrelate on blood viscosity after 24 weeks in
      patients with high blood viscosity.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to week 24 in tissue oxygen delivery index (tODI)</measure>
    <time_frame>baseline, week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 12 in tODI</measure>
    <time_frame>baseline, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with tODI elevated by 20% or more</measure>
    <time_frame>baseline, week 12, week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 24 in 36-Item Short Form Health Survey (SF-36)</measure>
    <time_frame>baseline, week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Peripheral Artery Disease, PAD</condition>
  <arm_group>
    <arm_group_label>Anplag Tab. 100mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sarpogrelate hydrochloride 100mg bid for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anplag Tab. 100mg tid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sarpogrelate hydrochloride 100mg tid for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anplag Tab. 100mg bid</intervention_name>
    <description>sarpogrelate hydrochloride 100mg bid for 24 weeks</description>
    <arm_group_label>Anplag Tab. 100mg bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anplag Tab. 100mg tid</intervention_name>
    <description>sarpogrelate hydrochloride 100mg tid for 24 weeks</description>
    <arm_group_label>Anplag Tab. 100mg tid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients diagnosed with PAD* (*Criteria for diagnosis of PAD: diagnosed with Burger's
             disease, obstructive arteriosclerosis, diabetic peripheral vascular disease, or with
             ischemic symptoms such as ulcers, pain, cold sensation, etc.)

          2. tODI &lt; 3 at randomization

          3. Aged ≥ 19 years

          4. Written informed consent

        Exclusion Criteria:

          1. Patients requiring acute or two or more antiplatelet agents

          2. Patients requiring anticoagulant therapy

          3. Patients requiring surgical procedure due to vascular occlusion

          4. Patients whose results are confirmed at the screening as follows:

               -  hemoglobin (Hb) test value: male &lt; 13 g/dL, female &lt; 12 g/dL

               -  platelet count &lt; 60,000/µL

               -  severe renal disease (eGFR &lt; 30 mL/min/1.73 m2)

          5. Patients with a history of cerebrovascular and cardiovascular complications (cerebral
             infarction, transient ischemic attack, myocardial infarction, unstable angina,
             coronary artery bypass, percutaneous coronary intervention) within the last 6 months

          6. Contraindications stated in the SPC of sarpogrelate

          7. Patients who are pregnant or planning to become pregnant

          8. Those participating in other clinical trials with administration of investigational
             products at the screening

          9. Those who are deemed to be ineligible to participate in the trial by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Catholic University of Korea, Uijeongbu ST. Mary's Hospital</name>
      <address>
        <city>Uijeongbu</city>
        <state>Gyeonggido</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2018</study_first_submitted>
  <study_first_submitted_qc>April 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2018</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarpogrelate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

